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REVIEW
THE INFLUENCE OF THE HUMAN GENOME ON CHRONIC VIRAL HEPATITIS OUTCOME
Dahir Ramos de ANDRADE JÚNIOR & Dahir Ramos de ANDRADE
SUMMARY
The mechanisms that determine viral clearance or viral persistence in chronic viral hepatitis have yet to be identified. Recent
advances in molecular genetics have permitted the detection of variations in immune response, often associated with polymorphism
in the human genome. Differences in host susceptibility to infectious disease and disease severity cannot be attributed solely to the
virulence of microbial agents. Several recent advances concerning the influence of human genes in chronic viral hepatitis B and C are
discussed in this article: a) the associations between human leukocyte antigen polymorphism and viral hepatic disease susceptibility
or resistance; b) protective alleles influencing hepatitis B virus (HBV) and hepatitis C virus (HCV) evolution; c) prejudicial alleles
influencing HBV and HCV; d) candidate genes associated with HBV and HCV evolution; d) other genetic factors that may
contribute to chronic hepatitis C evolution (genes influencing hepatic stellate cells, TGF-β1 and TNF-alpha production, hepatic iron
deposits and angiotensin II production, among others). Recent discoveries regarding genetic associations with chronic viral hepatitis
may provide clues to understanding the development of end-stage complications such as cirrhosis or hepatocellular carcinoma. In the
near future, analysis of the human genome will allow the elucidation of both the natural course of viral hepatitis and its response to
therapy.
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1. INTRODUCTION
Progress has been made in the tools used in the field of molecular
genetics. This greater knowledge has made it possible to detect immune
response variations, which are often associated with polymorphism in
the human genome, as well as facilitating the determination of correlation
between such polymorphism and disease mechanisms. The clinical
outcome of an infectious disease may be predetermined by genetic
polymorphism. Thus, differences in host susceptibility to infectious
disease and disease severity cannot be attributed solely to the virulence
of the microbial pathogen. Major histocompatibility complex (MHC)
gene products are vital in regulating several antiviral immune reactions.
In addition, genetic factors controlling the host immune response could
play an important role in determining infection outcome. Alloantigen
stimulation of the immune system requires that antigen-presenting cells
present antigens to antigen-specific T lymphocytes, a phase that is
dependent upon MHC compatibility. Alloantigens are taken up by
antigen-presenting cells, which process them and reexpress the antigens
on the cell surface, along with human leukocyte antigens (HLAs) to be
recognized by the T-cell receptor. The various HLA class II molecules
can differ by only a single amino acid, thus modifying their peptide-
binding ability. This can cause significant changes in the presentation of
the antigen to the T cell receptor, which in turn affects immune
response54,59.
Associations between HLA polymorphism and disease susceptibility
as well as disease resistance have been well investigated, especially in
autoimmune and metabolic diseases22,27. Moreover, correlations between
HLA polymorphism and clinical outcome for some viral infections have
been reported63. The mechanisms that determine clearance or viral
persistence in chronic viral hepatitis have not yet been identified. So far,
little is known about the potential role of host factors in chronic hepatitis
C virus (HCV) infection, or on the genetics of the immune response.
Genetic associations may also provide clues to the development of end-
stage complications such as cirrhosis or hepatocellular carcinoma. In
the near future, analysis of the human genome will allow researchers to
clarify the natural outcome of viral hepatitis and better determine its
response to therapy.
2. HEPATITIS AND THE HUMAN GENOME
2.1. Candidate Genes and Microsatellites: The genes that encode
products suspected of influencing the susceptibility or outcome of a
disease are called candidate genes. Within this group, there are genes
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that encode the chemokine receptor 5 (CCR5), which serves as a
coreceptor for the entry of human immunodeficiency virus (HIV) into
CD4 cells19, the NRAMP1 gene (involved in host susceptibility to
Mycobacterium tuberculosis infection)12,13, and the hemochromatosis
gene HFE (iron has been implicated in the viral hepatitis pathogenesis)14,
among others. One of the procedures used to identify a candidate gene
is the genome-wide scan, which uses densely distributed microsatellite
or single nucleotide polymorphism (SNP) markers to identify areas of
interest in the genome. Distortions in the frequencies of these markers
have been compared between one group of patients presenting positive
results and another group showing no positive results, as well as within
families presenting a disease phenotype20. If a specific disease has been
correlated with a marker, this marker will be found significantly more
often in those patients presenting the disease.
Microsatellite markers are tandem repeats of two to four base pairs
(bp), occurring approximately every 30 kilobases in the eukaryotic
genome. In a study involving several diseases with known HLA
associations, such as diabetes mellitus, narcolepsy, uveitis, C2 deficiency
and multiple sclerosis, significant correlations were found between these
diseases and the presence of microsatellites markers in proximity to the
disease gene15. Since they do not mutate as frequently, are more abundant
and are easier to analyze, SNPs (polymorphisms produced by a single
base change) may be superior to microsatellites. Denaturing high-
performance liquid chromatography or PCR methods may be used to
identify SNPs within the genome28,65.
2.2. HLA molecules and the Major Histocompatibility Complex
(MHC): The HLA complex consists of class I (HLA-A, -B, and -C) and
class II (HLA-DRB1, -DQA1, -DQB1, -DPA1, and -DPB1) alleles, which
are glycoproteins situated on the cellular surface and encoded by MHC
genes. Class I HLA molecules consist of a heavy 45-kDa chain and a
15-kDa β2 microglobulin chain. Class II HLA molecules are
heterodimeric and consist of alpha and beta chains of approximately 30-
kDa each. There are over 1000 different alleles that encode HLA class I
and class II molecules1. As primary step of immune response, HLAs
present antigens to both CD4+ helper T cells and CD8+ cytolytic T cells
(CTLs).
The MHC complex is located on the short arm of chromosome 6
and encodes several protein products involved in the immune response,
such as protein complement and TNF-α. Class I HLA molecules generally
present antigens that are generated endogenously, including epitopes
from viruses and other intracellular pathogens. In order to kill the infected
cell, CTLs must recognize the combination of viral epitope and class I
antigen coexpressed on the surface of hepatocytes. Class II HLA
molecules occur on antigen presenting cells (APCs) or dendritic cells
that present extracellularly derived antigens (including viral peptides)
to CD4+ T cells in order to stimulate cytokine release, thereby generating
humoral and cell-mediated immune responses. In acute HCV infection,
early host immune response is one of the determinants of viral persistence.
Class I HLAs, which present foreign antigens to CTLs, are integral
components of this response.
The HLA genes are the most diverse in the human genome, probably
due to an evolutionary adaptation to immune pressure from various
infectious agents. The serological typing of class I HLA molecules is
based on HLA-specific antibody binding to antigens on the cell surface.
Thus, polymorphisms in the unexposed peptide-binding groove, which
determines the antigenic epitopes presented to T cells, often escape
detection. At present, the most accurate methods for the typing of class
I HLAs involve combinations of PCR-SSP (polymerase chain reaction
sequence-specific primer), PCR-SSO (polymerase chain reaction
sequence-specific oligonucleotide), and direct sequencing11,12.
2.3. Candidate Gene Analysis: Linkage disequilibrium refers to the
non random association of alleles that causes a particular allelic
combination to occur more frequently than would be expected by chance.
For example, HLA-A1 and HLA-B8 occur in 27.5% and 15.7% of
Caucasians, although they would be expected to occur concomitantly
only in 4.3%67. This is due to the fact that HLA-A1 and HLA-B8 are in
linkage disequilibrium and form a haplotype75. Linkage disequilibrium
can occur as a consequence of genetic proximity or can result from
selection pressure that favors a particular combination of alleles even at
two distant loci.
Family studies can be used to provide clues to genetic susceptibility
to infectious disease. In these studies, individuals presenting a particular
disease comprise the initial group and their relatives are analyzed to
determine whether they also have increased susceptibility to the same
disease. By means of current molecular genetics technology, results from
disease association studies can be combined with family studies to
determine the inheritance pattern of a particular candidate gene.
Candidate gene polymorphism can be studied in a group of
individuals exposed to a particular infection. Most studies of HBV and
HCV have employed this particular method. However, these studies have
had some limitations related to inappropriate control groups and low
numbers of participants4,18,33,66.
Genetic epidemiological studies require large cohorts in order to
attain adequate statistical power. Studies that are HLA related also require
great numbers of individuals and regular distribution of alleles at some
of these loci. For example, for an allele with a frequency of 10%, 307
case-control pairs are needed to achieve an 80% chance of detecting a
two-fold disease correlation67.
Allele frequencies vary among ethnic groups, and many correlations
may only be detected in people of a particular ethnicity. A good example
is the CCR5 32-bp deletion polymorphism for HIV, which is found in
Caucasians but not in blacks49.
2.4. Human Genes and HBV
2.4.1. HBV and Protective Alleles: In economically developed
countries HBV is acquired in adulthood through sexual contact or
intravenous drug use, and chronic infection occurs in 5% to 10% of
cases25,44. In developing countries, where endemic levels of HBV are
high, acquisition usually occurs in childhood from either perinatal or
horizontal transmission.
Family studies in China have provided evidence that host genetic
factors may influence viral persistence. It has been shown that
concordance rates for AgHBe persistence were higher between identical
twins than between fraternal twins46. However, few family studies have
examined the genetic basis for susceptibility to HBV infection.
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Most genetic studies involving HBV susceptibility have focused on
its correlations with HLA I and HLA II53,78. In general, such studies
have used controls taken from the population at large, although there
have been seven studies that used controls that had previously been
infected with HBV and in whom the HBV infection had been
resolved4,33,66,72,77,78,85. None of the seven studies found a correlation
between class I alleles and viral persistence. In four of the seven studies
that compared viral persistence with viral clearance, correlations with
HLA class II alleles were noted4,33,66,72.
THURSZ et al. studied both children and adults in Gambia, and
found that the MHC class II allele HLA-DRB1*1302 was more frequent
in individuals that had cleared the infection than in those presenting
persistent infection72. The HLA-DRB1*1302 allele is also associated
with a reduced risk of severe malaria in Gambian children. Malaria and
HBV are both leading causes of premature death in West Africa. It is
possible that, in Gambians, there is a selective advantage for the
DRB1*1302 allele associated with both diseases72. A German study
examined the effect of DRB1*1302 in adults and also suggested that
this allele is protective against viral persistence33. In a study of Caucasian
subjects, a single class I allele (HLA-A*0301) was associated with HBV
clearance with an odds ratio (OR) of 0.4770.
A study of Qatari adults showed different correlations between HLA
class II alleles and HBV infection, and the results indicated that HLA-
DR2 was a protective factor3. Another study showed that HLA-DR6 and
HLA-DR13 were correlated with HBV clearance in Koreans2.
DOHERTY & ZINKERNAGEL21 anticipated that heterozygosity at
MHC loci could be advantageous for viral clearance since heterozygotes
have twice as many alleles with which to present antigens than do
homozygotes. A heterozygote for three class I loci (HLA-A, -B, and -
C), has six different alleles with which to present antigens, whereas a
homozygote has only three. Therefore, HIV-infected individuals who
are heterozygotes for HLA class I alleles are less likely to progress rapidly
to acquired immunodeficiency syndrome (AIDS)16.
Finally, the only reproducible correlation between host genes and
HBV infection involves HLA class II alleles. If specific alleles of the
class II loci are efficient for viral clearance or for slowing disease
progression, then it follows that a CD4+ helper T cell response would
be implicated as a critical factor in viral clearance. On the other hand,
HLA class I correlations would suggest that a CD8+ CTL response is
also a critical factor in eliminating HBV.
2.4.2. HBV Infection and Prejudicial Alleles: In a study involving
91 African-American adults who were regular intravenous drug users,
31 presenting self-limited HBV infections and 60 with persistent HBV
infections, HBV persistence was shown to correlate with the DQA1*0501
and DQB1*0301 alleles found in a common DQA1-DQB1 haplotype66.
The authors also found that the three loci of the DQA1*0501-
DQB1*0301-DRB1*1102 haplotype were significantly correlated with
viral persistence66. In another study, HLA-DRB1*0301, HLA-
DQA1*0501 and HLA-DQB1*0301 were found to be closely correlated
with susceptibility to chronic hepatitis B, whereas HLA-DRB1*1101/
1104 and HLA-DQA1*0301 were correlated with resistance to chronic
hepatitis B37.
The HLA-B*08 allele has been associated with B virus persistence
both independently (OR, 1.59) and as part of the conserved Caucasian
haplotype A*01-B*08 - DRB1*03. The B*44-Cw*1601 (OR, 2.23) and
B*44-Cw*0501 (OR, 1.99) haplotypes have also been associated with
viral persistence70. The HLA-DR7 allele was also found to be a risk
factor for hepatitis B in another study3. Further investigations have
demonstrated that HLA-DR9 was significantly more frequent in chronic
HBV carriers2.
2.4.3. Other Candidate Genes Associated with HBV: Genes that
encode tumor necrosis factor-alpha (TNF-α), as well as mannose binding
protein (MBP), and vitamin D receptor have been studied as potential
candidate genes, due to the role they may play in HBV pathogenesis.
Patients infected with HBV have increased levels of TNF-α and
upregulation of TNF-α receptors61. In addition, CTL secretion of TNF-
α was able to stop HBV gene expression in transgenic mice infected
with HBV29. It is possible that polymorphisms in the TNF-α gene may
influence HBV persistence. The TNF-α gene is located within the MHC
HLA class III region, and two polymorphism in its promoter region
(creating a biallelic polymorphism) at positions -308 and -238 alter TNF-
α expression. The –238 promoter variant was significantly correlated
with HBV persistence in a cohort of 71 chronically and 32 transiently
HBV infected German patients29,35,81.
Mutations in the mannose binding protein (MBP) gene (codons 52,
54 and 57), as well as in its promoter lead to low serum concentrations
of MBP, preventing both its ability to activate complement and to act as
an opsonin64. The HBV envelope has a mannose-rich oligosaccharide to
which MBP could bind. Therefore, these mutations may be important in
HBV pathogenesis71. The mutation of codon 52 in the MBP gene has
been correlated with persistent HBV infection in British Caucasians but
not in Chinese Asians71.
The active form of vitamin D, in addition to its role in calcium
regulation, is an immunomodulatory hormone that inhibits Th1 response
and activates Th2 response. The vitamin D receptor gene has two known
genetic polymorphisms that have been associated with several diseases
such as tuberculosis, leprosy and AIDS47. The tt genotype in one
polymorphism of vitamin D receptor gene was associated with HBV
clearance in another study13.
2.5. Human Genes and HCV
2.5.1. HCV and Protective Alleles: The HCV pathogen infects
individuals by the parenteral route6, and 75% to 85% of HCV infections
become persistent. The HCV antibody persists for years after HCV
infection, even in those individuals who present self-limited infections.
The presence of HCV RNA (detected by PCR) is used to differentiate
viral clearance from persistence. Viremia can be intermittent in the first
year of infection, and the presence of HCV RNA should be considered
when attempting to determine the outcome of an acute HCV infection79.
Genetic studies have examined four aspects of HCV infection: 1)
HCV clearance; 2) HCV evolution to cirrhosis; 3) susceptibility to HCV
infection; 4) HCV persistence.
Viral clearance may be defined as one positive anti-HCV test and
two negative viral RNA tests at least six months apart. Persistence is
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defined as continued HCV RNA positivity over a one-year period. In
addition, the degree of liver damage can be semiquantitatively assessed
by a system used to score liver biopsies40. Three studies have shown that
HCV clearance is associated with the DQB1*0301 allele5,18,52 and that
the DRB1*04 and DQA1*03 alleles are protective in strong linkage
disequilibrium with DQB1*030118. The DRB1*1101 allele is also in
linkage disequilibrium with DQB1*0301, and has been correlated with
HCV clearance5. A similar correlation has been found between the
DRB1*11 allele and HCV clearance52. In a study with an ethnically
diverse cohort, a weak correlation was found between HLA-DQB1*0301
and viral clearance in the combined ethnic groups (OR, 0.72), in contrast
to the stronger correlation found in black subjects. In Caucasian subjects,
viral clearance was correlated with DRB1*0101 (OR, 0.32) and its
DQB1*0501 haplotype68. In a study of patients with HCV infection,
YOSHIZAWA et al.84 showed higher frequency of DRB1*12 (*1201
and *1202), DQB1*0301 and DRB3*03 alleles in asymptomatic carrier
state (ACS) patients than in those with liver cirrhosis (LC) (OR, 11.23;
OR, 4.25; and OR, 3.22 respectively). The authors also showed that the
DQB1*0503 frequency was lower in ACS patients than in LC patients
(OR, 0.05). In another study, the HLA haplotype DRB1*1104/
DQB1*0301 appears to have contributed to the spontaneous clearance
of HCV infection48.
Two Japanese studies drew comparisons between HCV carriers with
normal liver function tests and normal hepatic histology, and HCV
patients with elevated liver enzymes and cirrhosis3,43. In these two studies,
no less than five HLA class II alleles were suggested as being protective
against HCV disease progression. Of the five alleles, only DRB1*1302
has been shown to have the same tendency for protection in another
study42. The DRB1*1101 allele has been correlated with viral clearance,
as well as with slower disease progression5,42.
PEANO et al.54 found an inverse correlation between frequency of
the HLA-DR5 antigen and the severity of liver disease. Several studies
have found class I and class II alleles to be correlated with HCV
infection17,31,32,73,78. In another work, it was shown that the DQA1*03
and DQB1*0302 alleles promote viral clearance and confer protection
against chronic HCV infection in Caucasians73. HOHLER et al. showed
that frequency of the DRB1*1302 allele is lower in HCV-infected
individuals than in controls32. This allele has been previously correlated
with slower disease progression42.
Two other recent studies identified additional haplotypes that correlate
with HCV clearance: in one of these, 25 RNA-HCV negative subjects
were compared with 103 RNA-HCV positive subjects in France, and
the DRB1*1101, DQA1*0501 and DQB1*0301 alleles were found to
be correlated with viral clearance5. In the other study, 49 RNA-HCV
negative subjects were compared with 55 RNA-HCV positive subjects
in Great Britain, and the DRB1*0401, DQA1*03 and DQB1*0301 alleles
were also found to be correlated with viral clearance18. The DQB1*0301
allele was the only one the two haplotypes had in common, suggesting
that this allele is important for HCV clearance.
The HLA class II allele, DRB1*11, was found at a reduced frequency
in 49 patients with chronic hepatitis C (anti-HCV and HCV RNA positive)
compared to controls (22.4 versus 51.0%; p < 0.01, OR = 0.3). The
authors state that there is a possibility that HLA-DRB1*11 contains a
protective feature in chronic HCV infection, hence this allele may also
be correlated with protection against HCV infection83. In addition,
patients with cirrhosis presented a lower DRB1*11 allele frequency (5.6%
vs. 14.5%) in another study36. TILLMANN et al.74 showed that the
presence of HLA-DRB1*11 and HLA-DQB1*03 alleles were associated
with a reduced risk for the development of HCV-induced end-stage liver
disease.
An additional study showed a high frequency of DRB1*1104 and
DQB1*0301 alleles in asymptomatic patients48. The DQB1*0301 and
DRB1*0401 alleles were frequently found in Irish patients presenting
viral clearance50.
To date, research into the association between HLA and spontaneous
HCV clearance has indicated that DR4, DR11 and/or DQB1*0301 alleles
are associated with viral clearance in European individuals3. In relation
to the role of DQB1*0301 allele in HCV clearance, a more rigorous
analysis of the other class II and class I alleles is essential in order to
determine whether this allele is simply an adjunct to the actual protective
allele at another HLA locus. Further studies involving HLA alleles are
necessary to determine the exact correlation with HCV clearance.
After several investigations into accidents involving contaminated
anti-D immunoglobulin performed in an Irish population, a better
understanding of the role of MHC class II alleles in HCV has been
gained9,23,24,39,56,57. Administration of contaminated anti-D
immunoglobulin resulted in the iatrogenic HCV genotype 1b infection
of 156 Irish women between May 1977 and November 1978. The
contaminated anti-D immunoglobulin was derived from a single infected
donor, and the study population was homogeneous in terms of gender,
source of infection, and ethnicity. In this group of studies, FANNING et
al.23,24 suggested that the HLA DRB1* 01 allele contributed to the
spontaneous resolution of a primary HCV infection in this population.
No correlations with either viral clearance or persistence were found at
the DQB1 locus. McKIERNAN et al.51 examined the correlation between
MHC and HCV infection status. The DRB1*0101 and DQB1*0501
alleles were more frequent in subjects who had achieved viral clearance
than in chronically infected subjects (32.3% and 36.8% versus 8.8%
and 14.2%, respectively; p = 0.002). Both DRB1* 03011 and DQB1*
0201 alleles were significantly less frequent in subjects presenting higher
inflammatory scores in liver biopsies.
THIO et al.69 showed that HLA-A*1101 (OR, 0.49), HLA-B*57
(OR, 0.62) and HLA-Cw*0102 (OR, 0.43) were correlated with viral
clearance. In a study of 21 German patients presenting self-limited HCV
infection, a higher frequency of the HLA-DR15 (B1*15011) allele was
observed in these patients than in patients with chronic hepatitis C44.
These data suggest that HLA-DR15 (B1*15011) might represent an
important genetic factor for the elimination of HCV in Germany.
2.5.2. HCV Infections and Prejudicial Alleles: The allele
DRB1*0301 (OR, 2.36) and its DQB1*0201 haplotype have been found
to be correlated with HCV persistence68. The predominance of the
DQB1*0502 allele in cirrhotic patients with rapid disease progression
may indicate an influence of this allele on the progression of the HCV-
related liver disease48.
In the two previously cited Japanese studies3,43, DQB1*0401,
DRB1*0405 alleles were more frequent in individuals who developed
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chronic HCV disease. In one of these studies, subjects with three-loci
haplotype HLA-B54-DQB1*0401-DRB1*0405 showed 13.2 times more
liver injury than those with the two-loci haplotype DQB1*0401-
DRB1*0405 (minus HLA-B54)43. In Japanese patients, the DR4 and
DQB1*0401 alleles were more frequent in HCV-infected individuals
than in controls31. Additionally, both of these alleles were associated
with a more rapid progression of HCV infection3.
One study showed that DRB1*03 and DQB1*0201 allele frequencies
appear to be higher in patients with HCV and cirrhosis36. The same authors
also found the mean index of fibrosis to be higher in DR3-positive patients
than in DR11-positive patients (2.14 vs. 1.58; p = 0.05)36. Similarly,
DRB1*0405 and DQB1*0401 alleles have been associated with more
severe disease in patients presenting cirrhosis3. In chronic hepatitis C
patients, a strong correlation between the HLA DRB1*11 allele and
persistence of normal ALT has been shown60.
Some studies have shown that the presence of DRB1*0701 in the
absence of DQB1*0501 may constitute influence of this allele in the
persistence of HCV infection23,24. In another study, DRB1*03011 and
DQB1*0201 alleles occurred more frequently in chronically infected
subjects than in those who had cleared the virus51.
It has also been shown that HLA-A*2301 (OR, 1.78) and HLA-
Cw*04 (OR, 1.78) correlate with HCV persistence69. In that study, HLA-
Cw*04 was reported to be in strong linkage disequilibrium with HLA-
B*53 and HLA-B*35, and only the Cw*04-B*53 haplotype (OR, 1.76)
correlated (albeit weakly) with viral persistence. Those authors also found
that, among persistently infected individuals, the HLA-Cw*04 allele
was correlated with HCV persistence, but not with HCV RNA levels.
According to the authors, since Cw*04 is a ligand for the killer
immunoglobulin-like receptors on natural killer cells, these cells may
be involved in recovery from HCV infection. They conclude that further
investigation is needed in order to understand the relationship between
class I alleles and HCV clearance69.
2.5.3. Other Candidate Genes Associated with HCV: Two other
candidate genes that have been studied in association with HCV persistence
are TNF-α and the hemochromatosis gene (HFE). Mutations in the TNF-
α gene have been suggested as candidate genes, because TNF-α levels are
elevated in HCV infection, probably due to CTL production in the liver41.
In a study of 82 persistent HCV infection patients and 99 controls, the –
238A TNF-α promoter variant was significantly correlated with persistent
infection34. In addition to playing a major role as mediator of the
inflammatory response, TNF-α downregulates collagen synthesis and may
promote apoptosis of either inflammatory or fibrogenic cells8.
The HFE gene has been studied in HCV infection due to the potential
effect of iron on HCV pathogenesis. Iron may promote HCV replication,
increase oxidative stress and impair host immunity17. Situated on
chromosome 6p, telomeric to the HLA-A complex, HFE is a MHC class-
I-like gene. This gene presents two identified mutations: the first at amino
acid position 282 (C282Y), and the second at amino acid position 63
(H63D). The protein encoded by the HFE gene may directly limit the
amount of iron absorbed in the small intestine, or may regulate gene
products that control iron absorption. As a whole these mutations lead
to increased iron absorption25. Some authors have investigated the role
of these mutations in individuals with chronic HCV infection and found
that the frequency of heterozygosity for the C282Y mutation in HCV-
infected patients with chronic active hepatitis is comparable to that found
in the general population30. Comparisons between chronically HCV
infected patients and random controls have revealed no differences in
the frequency of either mutation38. Another study involving chronic HCV
hepatitis patients has shown that individuals who are heterozygous for
the C282 mutation present a higher degree of fibrosis but only minor
increases in iron stores62. Overall, these data led us to conclude that the
HFE mutations contribute to, but do not fully explain, iron accumulation
in individuals with chronic HCV infection. Further studies are warranted
in order to increase understanding of this aspect.
Progressive hepatic fibrosis and cirrhosis develop in 20% to 30% of
patients with chronic hepatitis C. Although this phenomenon is linked
to HCV presence, it does not occur through HCV influence alone but
also depends on collagen production by Ito cells or hepatic stellate cells
(HSCs). These HSCs are situated between the endothelial lining and the
hepatocytes (Disse’s space), a site consistent with their role in the
recruitment of leukocytes and their targeting of damaged hepatocytes.
During the inflammatory phenomenon that occurs in hepatitis C, Kupffer
cells produce large quantities of secreted cytokines such as TNF-α and
Interferon-gamma. Cytokine secretion into the hepatic microenvironment
contributes to the activation of HSCs. The HSCs thus abandon their
quiescent state and begin storing vitamin D, as well as reaching an actively
proliferating myofibroblast-like cell state. Furthermore, HSC activation
is characterized by differential gene expression of connective tissue
components, matrix degrading enzymes, and their inhibitors, resulting
in matrix accumulation. Activated HSC produces several collagen types.
Anti-inflammatory cytokines, such as interleukin-10 (IL-10), which
presents prominent antifibrotic activity through downregulation of
collagen 1 expression, are also produced by HSCs80.
These recent findings concerning the role of HSCs in hepatic
fibrogenesis have produced notable consequences. More extensive
research has been carried out regarding blockade and inhibition of HSCs
and the resulting reduction in collagen production by these cells. In
addition, enzymes such as collagenases and tissue inhibitors of
metalloproteinases (TIMPs), as well as fibrogenic cytokines such as
transforming growth factor-beta 1 (TGF-β1) have been studied. Clearly,
HSCs are involved at all stages of the hepatic wound healing process.
There is evidence suggesting that HSCs initially participate in the
recruitment of inflammatory cells and subsequently contribute to the
reparative phase of wound healing through extracellular matrix
production. In the near future, these findings regarding HSC biology
and genetic control will be useful in order to improve the therapeutic
armamentarium available for better treatment of hepatic diseases.
Activation of HSCs and HSC production of extracellular matrix
proteins are both facilitated by the presence of TGF-β1. Messenger RNA
(mRNA) from TGF-β1 is increased in the liver of patients presenting
chronic HCV, and a correlation has been shown between TGF-β1 mRNA
expression and expression of type 1 collagen mRNA58.
Cytokine production capacity has a significant genetic component,
which explains why there are differences between individuals in their ability
to produce cytokines after in vitro stimulation of peripheral blood
leukocytes. This has been attributed to polymorphisms within the regulatory
regions of cytokine genes. For example, several polymorphic sites have
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been described within the TGF-β1 gene, including two in the promoter
region at -800 and -507 bp from the transcription start site, one at 72 bp,
and two in the signal sequence at codons 10 and 257. Another polymorphism
has been identified in the promoter region of the IL-10 gene, which contains
three biallelic polymorphisms at – 1082, -819, and – 592 bp from the
transcription start site. These three biallelic polymorphisms produce
haplotypes GCC, ACC and ATA, respectively75. Similarly the promoter
region of the TNF-α gene contains a biallelic polymorphism at position –
308 bp from the transcription start site82. Although inheritance of the high
TGF-β1 producing genotype is associated with the development of fibrotic
lung disease7, the role of these genetic polymorphisms in the progression
of other fibrotic diseases is unclear.
The genetic variability in factors influencing fibrogenesis may
account for some of the variability in disease progression seen in patients
with chronic hepatitis C. In a study of 128 patients with chronic hepatitis
C, a statistically significant correlation was shown between inheritance
of the genotypes for high production of TGF-β1 or angiotensinogen
(AT) and development of progressive hepatic fibrosis55. This suggests
that the angiotensin II, the principal effector molecule of the renin-
angiotensin system and a potent vasoconstrictor, may mediate production
of TBF-β1, thereby influencing the hepatic extracellular matrix11. Cell
culture studies have revealed that angiotensin II directly stimulates
transcription and bioactivation of TGF-β1 in several cell types: vascular
smooth muscle cells, renal proximal tubular cells, mesangial cells, cardiac
fibroblasts, and endothelial cells27.
Although there is currently no data confirming the existence of a
local renin-angiotensin system exists within the hepatic micro-
environment, the recent data concerning the presence of angiotensin
receptors on HSCs10 suggest that this might be an important area for
further research. Therefore, drugs that inhibit angiotensin II-mediated
TGF-β1 expression, such as ACE inhibitors and AII-receptor blockers
might be used to reduce hepatic fibrosis.
3. CONCLUSIONS
Further genetic studies performed in patients with chronic viral
hepatitis have contributed to the understanding of its pathogenesis.
Various MHC alleles that are correlated with more favorable outcomes
in cases of viral hepatitis have been identified in diverse populations.
The DRB1*1302, A*0301, DR2, DR6 and DR13 alleles are correlated
with better HBV outcomes, whereas DQB1*0301, DQB1*0201,
DQB1*03, DQA1*03, DRB1*01, DRB1*0101, DRB1*0301,
DRB1*04, DRB1*0401, DRB1*11, DRB1*12, DRB1*1101,
DRB1*1104, DRB1*1302, DRB3*03, DRQ1*1101, DQA1*03,
DQA1*0501, DQB1*0302, A*1101, B*57, Cw*0102, DR15 alleles are
correlated with better HCV outcomes. On the other hand, some studies
have shown correlation between specific alleles and less favorable clinical
outcomes for HBV and HCV patients. Identifying correlation between
specific genes and the evolution of viral hepatitis infection is the first
step toward greater understanding of the pathogenesis of hepatitis. The
next step will be finding correlations between these genes and immune
response. These findings will be useful in the near future in order to
develop appropriate therapeutic strategies for controlling viral hepatitis,
as well as to improve current knowledge regarding hepatitis prognosis.
Further studies involving different populations are necessary so that the
specific genes present in HBV and HCV patients may be identified.
RESUMO
A influência do genoma humano no curso das hepatites virais crônicas
Os mecanismos que determinam o clearance ou a persistência da
infecção viral nas hepatites virais crônicas não estão ainda bem
identificados. O progresso no conhecimento sobre as ferramentas
genéticas moleculares tem permitido detectar variações na resposta
imune, que freqüentemente são associadas com polimorfismos do genoma
humano. As diferenças na susceptibilidade do hospedeiro para as doenças
infecciosas e a intensidade das doenças não podem ser atribuídas apenas
à virulência do agente microbiano. Neste artigo são discutidos vários
avanços recentes no conhecimento sobre a influência dos genes humanos
nas hepatites crônicas B e C, a saber: a) As associações entre os
polimorfismos HLA e a susceptibilidade ou resistência às doenças
hepáticas virais; b) Alelos protetores influenciando as hepatites virais B
(HVB) e C (HVC); c) Alelos prejudiciais influenciando HVB e HVC; d)
Genes candidatos associados com a evolução clínica de HVB e HVC
(genes que influenciam as células estreladas do fígado, a produção de
TGF-β1 e TNF-α, os depósitos de ferro hepáticos, a produção de
angiotensina II, entre outros). O conhecimento das associações genéticas
com as hepatites virais crônicas pode fornecer indícios para o pleno
entendimento de como se desenvolvem as suas complicações terminais,
como a cirrose e o carcinoma hepatocelular. Em futuro próximo, a análise
do genoma humano será capaz de elucidar o curso natural de uma hepatite
viral, bem como a sua resposta à terapêutica.
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